Gilead CEO Milligan pulls in 11% pay raise amid waning revenues by Arlene Weintraub Tuesday, March 27, 2018 A host of challenges that drove Gilead's revenues down 14% last year didn’t stop its board from boosting the CEO’s pay package to $15.4 million.
What does Cigna's $54B Express Scripts buy mean for pharma? by Eric Sagonowsky Thursday, March 8, 2018 In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.
Gilead loses its commercial chief as it takes on daunting sales challenges by Arlene Weintraub Friday, February 23, 2018 Gilead's executive v.p. of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious-disease and oncology portfolios.
Payers ready to play tough with new NASH and migraine meds by Eric Sagonowsky Thursday, February 22, 2018 Look out, Amgen, Allergan, et al. PBMs are eyeing your forthcoming meds for pricing pressure—and as hep C drugmakers know, consequences can be brutal.
Gilead wins reversal of $2.54B verdict in Merck hep C case by Eric Sagonowsky Tuesday, February 20, 2018 The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead.
AbbVie's Mavyret takes a big bite from Gilead's hep C guidance by Eric Sagonowsky Wednesday, February 7, 2018 Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.
FiercePharmaAsia—Takeda, 2018 China nods, Sanofi and more by Angus Liu Friday, January 12, 2018 Takeda buys up TiGenix; some foreign drugs may be approved in China in 2018; Asian firms circle Sanofi's European generics unit.
Drug pricing pressure isn't likely to get worse: Merck CEO by Eric Sagonowsky Tuesday, January 9, 2018 The good news about drug pricing pressure, according to Merck CEO Ken Frazier? It won't get much worse.
16 blockbuster nods in 2018's China: report by Angus Liu Friday, January 5, 2018 Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
Gilead prices Sovaldi in China at one-fifth the U.S. price by Arlene Weintraub Tuesday, November 28, 2017 Gilead is introducing Sovaldi in China, where it faces mounting competitive pressure, at a steep discount.
